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A B S T R A C T
Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas
with an increasing incidence. The incidence, clinicopathologic characteristics, treatment and survival were assessed in
39 successive, newly diagnosed PGI-NHL patients (23 male and 16 female) treated at »Merkur« University Hospital. The
aim of the study was to precisely evaluate their characteristics and compare them with the results reported from other
similar studies. The most common site of PGI-NHL was stomach (n=29, 74%), followed by small intestine (n=5, 13%),
and colon and rectosigmoid (n=5, 13%). According to the Ann Arbor classification, 34 (87%) patients had stage IE and
IIE, and five patients (12%) stage IIIE and IVE. According to World Health Organization (WHO) classification, 29 (87%)
patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal
zone B-cell lymphoma-mucosa associated tissue (MALT). Twenty-six (66%) patients underwent surgical resection fol-
lowed by chemotherapy, ten (26%) were treated with chemotherapy alone, and three (8%) were treated surgically. Com-
plete remission was achieved in 28 (72%) and partial remission in seven (18%) patients. Four (10%) patients had progres-
sive disease. In our patients, the major prognostic factor for outcome was the stage of disease. Patients with localized
lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years. Patients
with extended disease (stage IIIE and IVE) had overall survival less than 33%. The prognostic power of erythrocyte sedi-
mentation rate (ESR), total protein, serum albumin, LDH concentration and activity was analyzed. Of these parameters,
only LDH had a statistically significant effect on overall survival. In conclusion, our patient group was comparable to
other literature reports on PGI-NHL patients according to clinicopathologic characteristics. Disease stage and LDHwere
the only parameters that had a statistically significant effect patient survival.
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Introduction
Primary non-Hodgkin lymphomas of gastrointestinal
tract (PGI-NHL) are the most common extranodal lym-
phomas, with an increasing incidence1,2. They account
for 30–50% of all extranodal lymphomas and constitute a
heterogeneous group of diseases with different clinical
and pathologic features3–5. The most common primary
site is stomach (60–75%), followed by small intestine, co-
lon, and rarely other gastrointestinal organs including
pancreas and liver5,6. Esophageal lymphoma is extremely
unusual, e.g. Mayo Clinic has reported only three pri-
mary cases in 47 years7.
There are many classifications of gastrointestinal tract
lymphomas, but none of them covers all requirements for
clinical and histopathologic use. For simplicity, clinical
staging has been evaluated according to Ann Arbor clas-
sification8 and histopathologic according to World Health
Organization (WHO) classification9. According to this
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classification, lymphomas of the gastrointestinal tract
generally fall into one of six categories (extranodal mar-
ginal zone-mucosa associated lymphoma tissue, MALT
lymphoma; follicular lymphoma; mantle cell lymphoma;
diffuse large B-cell lymphoma, DLCBL; and Burkitt’s
lymphoma)9,10.
Approximately one half to two-thirds of PG-NHL are
DLCBL11,12. MALT is the second most common type of
PGI- NHL, occurring predominantly in individuals aged
>50, with a peak in seventh decade, although it has been
occasionally reported in younger patients as well. In 80%
of cases, there is strong association between chronic
Helicobacter (H.) pylori infection and MALT gastric lym-
phoma13–15. Mantle cell, follicular and Burkitt’s lympho-
mas are encountered less frequently15.
Treatment strategies for nodal NHL are well estab-
lished, but there are still controversies concerning opti-
mal treatment of PGI-NHL, particularly gastric lym-
phoma. Surgery, radiotherapy, and chemotherapy have
been used alone or in combination16–20. Recently, impor-
tant improvement in the response rate for B-cell lympho-
mas has been achieved with CD20, a cytolytic antibody, a
direct agonist of the B cell specific antigen. Rituximab as
a single agent can induce overall objective response rates
in follicular lymphomas21.
In our retrospective study, the incidence, clinical fea-
tures, histology and treatment of PGI-NHL patients
treated at »Merkur« University Hospital during a 10-year
period were analyzed.
Patients and Methods
From January 1997 to January 2007, 548 patients
with NHL were diagnosed and treated at »Merkur« Uni-
versity Hospital in Zagreb. Among them, 39 (7%) pa-
tients with gastrointestinal symptoms or predominant
lesions in the gastrointestinal tract were selected for our
study as PGI-NHL. Characteristics of patients included
in the study are presented in Table 1. Diagnostic proce-
dure consisted of history and physical examination, com-
plete blood count and basic biochemical serum tests (in-
cluding lactate dehydrogenase, LDH), serum electropho-
resis with total proteins and chest X-ray and/or compute-
rized tomography, abdominal ultrasound, and endoscopic
examination of the gastrointestinal tract. Bone marrow
biopsy and aspirate were also obtained.
Twenty-two patients underwent esophagogastroduo-
denoscopy and seven colonoscopy, with multiple biopsies.
Four patients with stomach lymphoma had bleeding and/
or perforation and needed urgent surgical treatment. Six
patients with intestinal lymphoma also underwent ur-
gent surgical treatment because of obstructive symp-
toms. All tissue specimens were analyzed in the same de-
partment and were classified according to the WHO
classification of neoplasms of hematopoietic and lym-
phoid tissues9,10. Clinical staging was done according to
Ann Arbor classification8.
Patients were treated surgically, followed by chemo-
therapy, or by surgery or chemotherapy alone. None of
the patients was treated with radiotherapy. Antibiotic
therapy for H. pylori eradication was used in six positive
patients. Therapeutic response was assessed according to
standard criteria. Complete response was defined as
complete disappearance of all lymphoma signs, main-
tained for at least 6 weeks. Reduction of the disease bur-
den by at least 50% with disappearance of systemic mani-
festation for at least 6 weeks was considered as partial
response. Patients with stable or progressive disease
were classified as having no response22. Overall survival
was measured from the point of inclusion in the study to
the time of death from any cause or loss to follow up23.
On statistical analysis, c2-test was used to compare
response rates in the same groups of patients. Log-rank
test was used to compare survival between the groups.
Survival rate was calculated according to Kaplan-Meier
method. The level of significance was set at p<0.05. Sta-
tistical tests were performed by use of the Stat View v.
5.0.1 software (SAS Institute, Cary, NC, USA).
Results
Clinical and histologic findings of all patients are pre-
sented in Table 1. Out of 39 patients with PGI-NHL, 23
were males and 16 females (M:F ratio, 1.6:1) aged 20–74
(median 58) years. Most patients reported epigastric pain
(85%) and dyspepsia (30%). The duration of symptoms
before the diagnosis varied from a few weeks to several
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TABLE 1
CHARACTERISTICS OF 39 PATIENTS WITH PRIMARY
GASTROINESTINAL NON-HODGKIN LYMPHOMA
Age (yrs) Median 58
Range 20–74
Sex: M/F 23/16
Histologic Subtypes
High grade
Diffuse large cell B lymphoma (DLCBL) 29
Mantle-cell lymphoma 2
Low grade
Mucosa associated lymphoma tissue (MALT) 8
Stage
I 13
II 21
III–IV 5
Bone Marrow
Positive 4
Negative 28
Not done 7
Distribution
Stomach 29
Jejunum/ileum 5
Colon/ rectosigmoid 5
months. Weight loss before the diagnosis was reported by
40% of patients. At the time of diagnosis, gastric bleeding
was the main symptom in 15%–20% of patients, while
perforation was rare.
Thirty four (88%) patients had disease stage IE and
IIE, while five (12%) patients had stage IIIE and IVE. B
symptoms (fever, weight loss of more than 10 percent of
body weight and night sweats) were present in 33% of
our patients, most of them with DLCBL.
According to histopathologic classification, DLCBL
accounted for 74%, MALT for 21% and mantle cell lym-
phomas for 5% of all PGI-NHL cases. Bone marrow infil-
tration was positive in only four (10%) patients. There
was no age and sex difference in the relative incidence of
MALT lymphoma and DLCB lymphoma. Disease charac-
terization was similar, with the exception of LDH, which
was more frequently elevated in DLCBL patients.
Out of 39 PGI-NHL patients, 26 patients with DLCBL
underwent surgical resection followed by 3–6 cycles of
chemotherapy. Twenty-one of them were treated with
CHOP regimen that consists of cyclophosphamide, doxo-
rubicin, vincristine, and prednisone. Therapy was re-
peated every three weeks. Four patients were treated
with chemotherapy without an anthracycline (COP), be-
cause they were older than 65 or had cardiomyopathy
with ejection fraction <55%. After surgical intervention,
one patient was treated with an alkylating agent (chlo-
rambucil) in combination with prednisone.
Three patients with DLCBL were treated with chemo-
therapy (CHOP) and immunotherapy (rituximab). They
were administered rituximab several years ago, when it
was registered for this indication. Two patients with
mantle cell lymphoma were also treated with chemother-
apy (CHOP) and immunotherapy (rituximab). One of
them relapsed two years later and was then treated with
myeloablative chemotherapy followed by autologous bo-
ne marrow transplantation, while the other was trans-
planted immediately after surgery. Now, both patients
are in remission.
Five patients with MALT lymphoma were treated
only with chemotherapy. Two patients had stage IE gas-
tric MALT lymphoma and positive H. pylori test. They
immediately received therapy for H. pylori eradication
that consisted of amoxicillin, metronidazole, and ome-
prazole. Both achieved remission, however, relapse oc-
curred at one year. Then, they were treated with chemo-
therapy with alkylating agents and prednisone. Three
other patients with MALT lymphoma underwent surgery
and adjuvant chemotherapy (COP).
The overall response rate was 84% at 5 years and 68%
at 10 years (Figure 1). Complete response was achieved
in 28 (71%) and partial remission in seven (23%) pa-
tients, whereas four patients had progressive disease. Pa-
tients with stage IE-IIE tended to live longer than those
with stage IIIE-IVE (p<0.005), but there was no signifi-
cant difference in the overall survival between patients
with DLCBL and MALT (Figure 2). Furthermore, there
was no difference in survival between patients with local-
D. Radi}-Kri{to et al.: Primary Gastrointestinal NHL in Adults, Coll. Antropol. 34 (2010) 2: 413–417
415
0
,2
,4
,6
,8
1
0 20 40 60 80 100 120 140
Time
Kaplan-Meier Cum. Survival Plot for TTmonths
Censor Variable: status
C
u
m
. S
u
rv
iv
al
Fig. 1. Overall survival in 39 patients with primary
gastrointestinal non-Hodgkin lymphoma.
Fig. 2. Survival according to clinical stage: low stages I+II–L,
high stages III+IV–H (p=0.0008).
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Fig. 3. Survival according to treatment: CT – chemotherapy,
Combination – chemotherapy plus surgery (p>0.05).
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Fig. 4. Survival according to LDH: LDH400 – LDHHigh,
LDH<400 – LDHLow (p<0.0001).
ized disease treated with surgery with or without chemo-
therapy, and those treated with chemotherapy alone (Fi-
gure 3). Finally, in our study LDH activity was found to
be an important prognostic factor; patients with higher
LDH levels had lower overall survival (Figure 4), whe-
reas other parameters analyzed (ESR, albumin, total
proteins, age and sex) had no statistically significant ef-
fect on patient prognosis.
Discussion and Conclusion
Primary gastrointestinal non-Hodgkin lymphoma is a
heterogeneous disease regarding patient characteristics,
histologic subtypes, stage, and treatment results. It is es-
timated that 11%–34% of all NHL are PGI-NHL1. The
most commonly involved site is stomach with a fre-
quency of 37.5%–86% in several studies, followed by
small intestine, colon and rectum2–7. In our retrospective
study, survival was analyzed in 39 patients with PGI-
-NHL. Out of 548 patients diagnosed and treated at
»Merkur« University Hospital from January 1997 till
January 2007, the prevalence of PGINHL was 7%. Stom-
ach was the main site in approximately 74% of all PGI-
-NHL cases, which is in agreement with other literature
reports1–7. Our results confirmed PGI-NHL to occur
more frequently in men than in women24. The most com-
mon histologic subtypes were DLCBL and marginal zone
B cell lymphoma-mucosa associated tissue. In our study,
the percentage of DLCBL was higher than of MALT lym-
phoma (71% vs. 20%), which is consistent with literature
data7,11,15. However, in the study by Papaxoinis et al., the
percentage of indolent lymphoma (MALT) was slightly
higher than that of aggressive lymphoma (DLCBL), pro-
bably because of the higher prevalence of H. pylori infec-
tion20. H. pylori infection is considered to be involved in
the pathogenesis of MALT lymphoma, while its role in
the etiology of DLCBL is controversial22,23.
In the present study, the stage of disease was the ma-
jor prognostic factor. Patients with localized lymphoma
stage IE and IIE had a significant longer overall survival
than patients with extended disease. At 3 years of the di-
agnosis, the overall survival in patients with stage IE and
IIE (85%) was significantly higher (p<0.05) than in pa-
tients with stage IIIE and IVE. Similar results has been
reported from other studies where overall survival in ad-
vanced PGI-NHL ranged from 25% to 47%11,12,14,15,18.
Also, in our study LDH activity had a statistically signifi-
cant effect on overall survival, while other study parame-
ters such as ESR, albumin, total protein, age and sex had
no statistically significant impact on prognosis. In our
study, there was no difference in overall survival between
patients with DLCBL and MALT lymphoma, which is in
contrast with the study by Koch et al.15, where a signifi-
cantly shorter overall survival was only found in patients
with high grade gastrointestinal lymphoma.
Although the management of primary gastrointesti-
nal lymphoma, particularly of gastric origin, has been ex-
amined in several studies reported in the literature, it re-
mains controversial. Many studies were focused on pri-
mary resection and chemotherapy18,20,25. However, other
authors found no difference in survival between patients
treated with chemotherapy and those treated with sur-
gery plus chemotherapy12–15. In a randomized study of
survival of patients with gastric DLCBL after chemo-
therapy or surgery combined with chemotherapy, sur-
vival was significantly longer (10-year survival rates 96%
and 91%, respectively) than after surgery alone or sur-
gery in combination with radiotherapy (10-year survival
rate 53%)17. In our study, there was no difference in over-
all survival between patients treated with surgery plus
chemotherapy and patients treated with chemotherapy
alone (Figure 3).
In conclusion, PGI-NHL is a heterogeneous disease
characterized by high variability of clinicopathologic and
demographic features. Stage is the most important prog-
nostic factor, with a significantly better survival in local-
ized as compared with extended disease. Optimal treat-
ment has not yet been established. New intensive combi-
nations of chemotherapy, immunotherapy, radioimmuno-
therapy and radiotherapy, randomized clinical trials with
a large number of patients and long-term follow up are
needed to find out and validate the most appropriate
treatment for PGI-NHL.
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PRIMARNI NE-HODGKINOV LIMFOM PROBAVNOG SUSTAVA
S A @ E T A K
Primarni ne-Hodgkinov limfom (NHL) probavnog sustava naj~e{}i je oblik ekstranodalnih limfoma s incidencijom
rasta. U Klini~koj bolnici »Merkur« retrospektivno smo analizirali 39 novodijagnosticiranih bolesnika (23 mu{karca, 16
`ena). Analizirali smo klini~ko patolo{ke karakteristike, na~in lije~enja i pre`ivljenje bolesnika u razdoblju od sije~nja
1997. do sije~nja 2007. godine. U 29 (74%) bolesnika dijagnosticiran je NHL `eluca, u 5 (13%) tankog crijeva, a u 5 (13%)
debelog crijeva. Klini~ki stadij bolesti odredili smo prema klasifikaciji Ann Arbor. Klini~ki stadij IE i IIE imalo je 34
(87%) bolesnika, dok je 5 (12%) bolesnika imalo stadij IIIE i IVE. Prema klasifikaciji Svjetske zdravstvene organizacije
(SZO) 29 (87%) bolesnika imalo je B velikostani~ni limfom, 2 (5%) limfom pla{tene zone, a 7 (18%) bolesnika imalo je
limfom marginalne zone (MALT). Prema na~inu lije~enja 26 (66%) bolesnika lije~eno je operacijski (potpuna ili dje-
lomi~na gastrektomija ili resekcija) nakon ~ega su primali kemoterapiju, 10 (26%) bolesnika samo kemoterapijom, a 3
(8%) bolesnika samo operacijskim lije~enjem. Kompletna remisija postignuta je u 28 (72%), djelomi~na remisija u 7
(18%) bolesnika, a u 4 (10%) bolesnika do{lo je do progresije bolesti. Bolesnici s klini~kim stadijem IE i IIE imali su
znatno du`e pre`ivljenje (5-godi{nje pre`ivljenje 85% bolesnika i 10-godi{nje 65% bolesnika) od bolesnika u IIIE ili IVE
stadiju bolesti koji su imali pre`ivljenje manje od 33%. U studiji se analizirao i utjecaj ostalih parametara (dob, spol, SE,
serumski albumini, ukupni proteini i laktat dehidrogenaza – LDH) na prognozu bolesnika. Jedini parametri koji su
imali statisti~ki zna~ajan (p<0,05) utjecaj na pre`ivljenje bili su stadij bolesti i vrijednost LDH.
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